Pulmatrix (PULM) Return on Capital Employed (2014 - 2026)
Pulmatrix (PULM) posted Return on Capital Employed of 135.21% for Q1 2026, down 10.69% sequentially from 122.16% in Q4 2025, and up 1746.0% YoY from 7.32% in Q1 2025.
Pulmatrix (PULM) Return on Capital Employed (2014 - 2026) Analysis & Trends
Pulmatrix has reported Return on Capital Employed for 13 years, with the latest figure at 135.21% in Q1 2026.
- Quarterly Return on Capital Employed rose 1746.0% year-over-year to 135.21% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 135.21% (up 1746.0% YoY) and the FY2025 annual result came in at 77.01%, down 3057.0% from the prior year.
- Return on Capital Employed slipped to 135.21% in Q1 2026 per PULM's latest filing, from 122.16% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 32.41% in Q1 2024 and troughed at 152.67% in Q1 2025.
- A 5-year average of 77.25% and a median of 56.79% in 2023 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed jumped 2257 bps in 2024, then plunged 12026 bps in 2025.
- Over 5 years, Return on Capital Employed stood at 48.98% in 2022, then rose by 4 bps to 46.86% in 2023, then sank by 113 bps to 99.65% in 2024, then decreased by 23 bps to 122.16% in 2025, then fell by 11 bps to 135.21% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 135.21%, 122.16%, and 116.83% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Pulmatrix | 5.46 Mn | 5.46 Mn | - | -129.23% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -129.23% |
| Mar 31, 2026 | -135.21% |
| Dec 31, 2025 | -122.16% |
| Sep 30, 2025 | -116.83% |
| Jun 30, 2025 | -122.13% |
| Mar 31, 2025 | -152.67% |
| Dec 31, 2024 | -99.65% |
| Sep 30, 2024 | -76.87% |
| Jun 30, 2024 | -54.90% |
| Mar 31, 2024 | -32.41% |
| Dec 31, 2023 | -46.86% |
| Sep 30, 2023 | -56.79% |
| Jun 30, 2023 | -59.75% |
| Mar 31, 2023 | -54.98% |
| Dec 31, 2022 | -48.98% |
| Sep 30, 2022 | -44.87% |
| Jun 30, 2022 | -47.04% |
| Mar 31, 2022 | -41.12% |
| Dec 31, 2021 | -38.17% |
| Sep 30, 2021 | -33.90% |